中国中医药信息杂志
中國中醫藥信息雜誌
중국중의약신식잡지
CHINESE JOURNAL OF INFORMATION ON TRADITIONAL CHINESE MEDICINE
2013年
11期
8-10
,共3页
王会丽%高天曙%杨小平%赵玉瑶
王會麗%高天曙%楊小平%趙玉瑤
왕회려%고천서%양소평%조옥요
慢性乙型病毒性肝炎%乙肝e抗原%臌胀片%替比夫定%减毒增效
慢性乙型病毒性肝炎%乙肝e抗原%臌脹片%替比伕定%減毒增效
만성을형병독성간염%을간e항원%고창편%체비부정%감독증효
chronic hepatitis B%HBeAg%meteorism tablets%telbivudine%attenuated and synergistic effect
目的观察臌胀片在乙肝 e 抗原(HBeAg)阳性慢性乙型病毒性肝炎治疗中的减毒增效作用。方法将80例HBeAg阳性慢性乙型肝炎患者随机分为治疗组(臌胀片联合替比夫定)和对照组(替比夫定),均治疗1年,观察治疗前后2组患者丙氨酸氨基转移酶(ALT)、天冬氨酸氨基转移酶(AST)、乙肝病毒-DNA(HBV-DNA)阴转率、HBeAg阴转率、HBeAg/HBeAb血清学转换率、血清肌酸激酶(CK)水平及安全性。结果治疗48周后,治疗组ALT、AST、HBV DNA阴转率、HBeAg阴转率及HBeAg/HBeAb血清学转换率均优于对照组(P<0.05)。2组患者均有CK升高,其中治疗组13例(32.5%),对照组24例(60.0%),2组比较差异有统计学意义(P<0.05)。结论臌胀片与替比夫定联合用药后,其减毒增效作用显著。
目的觀察臌脹片在乙肝 e 抗原(HBeAg)暘性慢性乙型病毒性肝炎治療中的減毒增效作用。方法將80例HBeAg暘性慢性乙型肝炎患者隨機分為治療組(臌脹片聯閤替比伕定)和對照組(替比伕定),均治療1年,觀察治療前後2組患者丙氨痠氨基轉移酶(ALT)、天鼕氨痠氨基轉移酶(AST)、乙肝病毒-DNA(HBV-DNA)陰轉率、HBeAg陰轉率、HBeAg/HBeAb血清學轉換率、血清肌痠激酶(CK)水平及安全性。結果治療48週後,治療組ALT、AST、HBV DNA陰轉率、HBeAg陰轉率及HBeAg/HBeAb血清學轉換率均優于對照組(P<0.05)。2組患者均有CK升高,其中治療組13例(32.5%),對照組24例(60.0%),2組比較差異有統計學意義(P<0.05)。結論臌脹片與替比伕定聯閤用藥後,其減毒增效作用顯著。
목적관찰고창편재을간 e 항원(HBeAg)양성만성을형병독성간염치료중적감독증효작용。방법장80례HBeAg양성만성을형간염환자수궤분위치료조(고창편연합체비부정)화대조조(체비부정),균치료1년,관찰치료전후2조환자병안산안기전이매(ALT)、천동안산안기전이매(AST)、을간병독-DNA(HBV-DNA)음전솔、HBeAg음전솔、HBeAg/HBeAb혈청학전환솔、혈청기산격매(CK)수평급안전성。결과치료48주후,치료조ALT、AST、HBV DNA음전솔、HBeAg음전솔급HBeAg/HBeAb혈청학전환솔균우우대조조(P<0.05)。2조환자균유CK승고,기중치료조13례(32.5%),대조조24례(60.0%),2조비교차이유통계학의의(P<0.05)。결론고창편여체비부정연합용약후,기감독증효작용현저。
Objective To observe the attenuated and synergistic effect of meteorism tablets in treating HBeAg-positive chronic hepatitis B patients. Methods Eighty patients of HBeAg-positive chronic hepatitis B were randomly divided into treatment group (meteorism tablets combined with telbivudine) and control group (telbivudine), and treated for one year. The changes of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), the negative rate of HBV-DNA, the negative rate of HBeAg, HBeAg/HbeAb serological conversion rate, creatine kinase (CK) before and after treatment, and safety were observed. Results After treatment, biochemical response, virological response and HBeAg serological response was more significant in the treatment group than that in the control group (P<0.05). The percetage of patients with elevated CK in the treatment group was significantly lower than that in the control group (32.5% vs 60%, P<0.05). Conclusion Meteorism tablets combined with telbivudine has attenuated and synergistic effect in treating HBeAg-positive chronic hepatitis B patients.